Ocugen shares are trading lower. The company announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen shares are trading lower. The company announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.